Neuphoria Therapeutics Inc. Research and Development Expense
Neuphoria Therapeutics Inc. (NEUP) reported Research and Development Expense of $697.72 thousand for the 3-month period ending 2025-12-31, per its 10-Q filed 2026-02-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-02-17
- Neuphoria Therapeutics Inc. research and development expense for the quarter ending 2025-12-31 was $697.72K, a 59.83% decline year-over-year.
- Neuphoria Therapeutics Inc. research and development expense for the quarter ending 2025-09-30 was $3.79M, a 99.15% increase year-over-year.
- Neuphoria Therapeutics Inc. research and development expense for the quarter ending 2025-06-30 was $3.75M, a 21.16% increase year-over-year.
- Neuphoria Therapeutics Inc. research and development expense for the quarter ending 2025-03-31 was $1.62M, a 34.83% increase year-over-year.
- Neuphoria Therapeutics Inc. research and development expense for fiscal 2025 was $9.01M, a 4.38% decline from fiscal 2024.
- Neuphoria Therapeutics Inc. research and development expense for fiscal 2024 was $9.42M, a 27.95% decline from fiscal 2023.
- Neuphoria Therapeutics Inc. research and development expense for fiscal 2023 was $13.07M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $697.72K 10-Q · filed 2026-02-17 | $4.48M 10-Q · filed 2026-02-17 | $8.23M derived: sum of 3 quarters · filed 2026-02-17 | $9.85M derived: sum of 4 quarters · filed 2026-02-17 |
| 2025-09-30 | $3.79M 10-Q · filed 2025-11-14 | $7.54M derived: sum of 2 quarters · filed 2025-11-14 | $9.15M derived: sum of 3 quarters · filed 2025-11-14 | $10.89M derived: sum of 4 quarters · filed 2026-02-17 |
| 2025-06-30 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $5.37M derived: sum of 2 quarters · filed 2025-09-29 | $7.10M derived: sum of 3 quarters · filed 2026-02-17 | $9.01M 10-K · filed 2025-09-29 |
| 2025-03-31 | $1.62M 10-Q · filed 2025-05-20 | $3.35M derived: sum of 2 quarters · filed 2026-02-17 | $5.25M 10-Q · filed 2025-05-20 | $8.35M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-12-31 | $1.74M 10-Q · filed 2026-02-17 | $3.64M 10-Q · filed 2026-02-17 | $6.73M derived: sum of 3 quarters · filed 2026-02-17 | $7.93M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | $1.90M 10-Q · filed 2025-11-14 | $5.00M derived: sum of 2 quarters · filed 2025-11-14 | $6.20M derived: sum of 3 quarters · filed 2025-11-14 | $8.23M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $4.29M derived: sum of 2 quarters · filed 2025-09-29 | $6.33M derived: sum of 3 quarters · filed 2025-09-29 | $9.42M 10-K · filed 2025-09-29 |
| 2024-03-31 | $1.20M 10-Q · filed 2025-05-20 | $3.23M derived: sum of 2 quarters · filed 2025-05-20 | $6.32M 10-Q · filed 2025-05-20 | |
| 2023-12-31 | $2.03M 10-Q · filed 2025-02-14 | $5.12M 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | $3.09M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $13.07M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |